Trevor is an intellectual property lawyer who advises clients on the commercialisation and enforcement of their IP rights, with a particular focus on patent and licensing disputes in the biotechnology and pharmaceutical sectors. His primary expertise lies in biopharmaceutical patent and SPC litigation, in which he regularly advises clients in relation to complex technical disputes.
Trevor has advised clients on actions in the High Court, Court of Appeal and Intellectual Property Enterprise Court, as well as in relation to references to the Court of Justice of the European Union. His work routinely involves multi-jurisdictional disputes and he has significant experience co-ordinating global litigation strategies for his clients.
Trevor qualified as a solicitor in 2009 and joined Marks & Clerk Law in 2010. He became a partner of the firm in 2019.
Trevor has been recognised as a rising star by Managing Intellectual Property, IP Stars, 2018.
Eli Lilly v Genentech (Anti-IL17A/F antibodies)
Chugai Pharmaceutical Co v UCB Pharma (Antibody humanisation protocols)
Fujifilm Kyowa Kirin Biologics v AbbVie (Humira therapy for Crohn’s disease)
Fujifilm Kyowa Kirin Biologics v AbbVie (Humira dosing regimen)
Hospira UK v Genentech (Herceptin combination therapy)
Hospira UK v Genentech (Herceptin formulation)
Hospira UK v Genentech (Herceptin dosing regimen)
Regeneron Pharmaceuticals v Genentech (VEGF antagonists)
MedImmune v Novartis (Phage display)
Postgraduate Diploma in Intellectual Property Law and Practice, Oxford University (2012)
Qualified as a Solicitor in England & Wales (2009)
Legal Practice Course, College of Law, Birmingham (2006)
Graduate Diploma in Law, College of Law, Birmingham (2005)
BSc Microbiology with Immunology, University of Leeds (2003)